Furthermore, the use of NKA activators has been associated with increased osteogenic differentiation in mesenchymal stem cells, suggesting a broader therapeutic potential for NKA modulation beyond metabolic diseases (48). The gene discussed is TAC1; the disease is metabolic disease.